Wolfe Research Begins Coverage on Genmab A/S (NASDAQ:GMAB)

Stock analysts at Wolfe Research began coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $32.00 price target on the stock. Wolfe Research’s price target suggests a potential upside of 23.93% from the company’s current price.

Several other brokerages also recently commented on GMAB. Wells Fargo & Company assumed coverage on shares of Genmab A/S in a report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price target on the stock. Morgan Stanley initiated coverage on shares of Genmab A/S in a research note on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price objective for the company. Truist Financial upgraded Genmab A/S to a “strong-buy” rating in a research report on Wednesday. Jefferies Financial Group initiated coverage on Genmab A/S in a research note on Tuesday, February 17th. They set a “buy” rating and a $41.50 target price on the stock. Finally, Guggenheim reduced their price target on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $39.36.

Genmab A/S Stock Down 0.8%

Shares of GMAB opened at $25.82 on Friday. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86. The business has a fifty day moving average of $29.40 and a 200 day moving average of $30.47. The company has a market cap of $16.59 billion, a PE ratio of 16.66, a P/E/G ratio of 1.06 and a beta of 0.94. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $35.43.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. On average, sell-side analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GMAB. CIBC Private Wealth Group LLC boosted its position in Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after buying an additional 616 shares during the period. Osaic Holdings Inc. increased its position in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after acquiring an additional 440 shares during the period. NewEdge Advisors LLC increased its position in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after acquiring an additional 1,143 shares during the period. Brown Brothers Harriman & Co. raised its stake in shares of Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after acquiring an additional 780 shares in the last quarter. Finally, Founders Capital Management raised its stake in shares of Genmab A/S by 40.0% during the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.